Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

What's the purpose of this trial?

This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation (alloHCT) for patients with hematologic malignancies with bone marrow involvement of their relapsed disease. 

This trial is currently open and accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Age ≥18 years old
  • Bone marrow relapse of a hematologic malignancy ≥6 months after alloHCT using PTCy
  • Donor CD3+ chimerism ≥ 30% measured in peripheral blood or bone marrow
  • ECOG performance status ≤ 2 or Karnofsky performance scale ≥ 70%.
  • Off all immunosuppressive drugs for 2 weeks prior to the PTCy-MILs collection.
  • Expectation of ability to safely undergo salvage treatment appropriate for the patient's malignant disease type as determined by the treating hematologist/ oncologist.

Exclusion Criteria:

  • Most recent alloHCT not utilizing PTCy.
  • Active GVHD requiring treatment.
  • Immunosuppression use within 28 days of PTCy-MIL infusion if prior grade II-IV acute GVHD.
  • Creatinine ≥ 2.5, total bilirubin > 3 times the upper limit of normal (ULN), or AST/ALT > 3 times the ULN.
  • HIV-1/2 or HTLV-1/2 positivity.
  • Life expectancy ≤ 90 days even with aggressive treatment, as determined by the treating hematologist/oncologist, which would preclude assessment of toxicity of PTCy-MILs

Additional Trial Information

Phase 1

Enrollment: 27 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Maryland

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine

Baltimore, MD

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message